13603-45-7

Basic information

• Product Name: 4-HYDROXY-3-NITRO-2,6-DIMETHYLPYRIDINE
• Synonyms: 4-HYDROXY-3-NITRO-2,6-DIMETHYLPYRIDINE;2,6-Dimethyl-3-nitro-4-pyridinol;2,6-DiMethyl-3-nitropyridin-4-ol;2,6-DiMethyl-4-hydroxy-3-nitropyridine
• CAS NO: 13603-45-7
• Molecular Formula: C7H8N2O3
• Molecular Weight: 168.15
• Mol File: 13603-45-7.mol

Chemical Properties

• Melting Point: 296 °C
• Boiling Point: 363.7±37.0 °C(Predicted)
• Appearance: /
• Density: 1.340±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 0.15±0.33(Predicted)
• CAS DataBase Reference: 4-HYDROXY-3-NITRO-2,6-DIMETHYLPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDROXY-3-NITRO-2,6-DIMETHYLPYRIDINE(13603-45-7)
• EPA Substance Registry System: 4-HYDROXY-3-NITRO-2,6-DIMETHYLPYRIDINE(13603-45-7)

Safety Data

• Hazardous Substances Data: 13603-45-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-HYDROXY-3-NITRO-2,6-DIMETHYLPYRIDINE is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure and reactivity make it a key component in the development of new drugs and medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical sector, 4-HYDROXY-3-NITRO-2,6-DIMETHYLPYRIDINE is utilized as an intermediate in the production of agrochemicals. Its properties contribute to the formulation of effective pesticides and other agricultural chemicals that enhance crop protection and yield.
Used in Dye and Pigment Production:
4-HYDROXY-3-NITRO-2,6-DIMETHYLPYRIDINE is employed as a building block in the creation of various dyes and pigments. Its chemical structure allows for the development of a wide range of colorants used in different industries, including textiles, plastics, and printing inks.
Used in Chemical Research and Development:
NDMP is also used as a precursor in various chemical processes and applications, particularly in research and development. Its high reactivity and potential for modification make it an essential component in the exploration of new chemical reactions and the synthesis of novel compounds.

Upstream product

• 7516-31-6 2,6-dimethyl-1H-pyridin-4-one 
• 92247-78-4 1-benzyl-2,6-dimethyl-1H-pyridin-4-one 
• 1004-36-0 2,6-dimethylpyrone 
• 13603-44-6 2,6-dimethylpyridin-4-ol 

Downstream Products

• 15513-48-1 4-chloro-2,6-dimethyl-3-nitropyridine 
• 328554-54-7 2,6-dimethyl-4-(4-fluorophenylamino)-3-nitropyridine 
• 328554-55-8 3-amino-2,6-dimethyl-4-(4-fluorophenylamino)pyridine 
• 409316-67-2 3-amino-2,6-dimethylpyridin-4-ol 

Relevant articles and documents

COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatmen

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers. Epigenetic modifications play an important role in the regulation of many cellular processes including cell proliferation, differentiation, and cell survival. Global epigenetic modifications are common in cancer, and include global changes in DNA and/or histone methylation, dysregulation of non-coding RNAs and nucleosome remodeling leading to aberrant activation or inactivation of oncogenes, tumor suppressors and signaling pathways.

Syntheses of 4- and 6-substituted thiazolo[4,5-c]pyridines

A general synthetic approach to 4,6-substituted thiazole[4,5-c]pyridines, involving a novel one-pot thiol deprotection-cyclization key step, is described.

Inhibitors of acyl-CoA:cholesterol O-acyltransferase. 3. Discovery of a novel series of N-alkyl-N-[(fluorophenoxy)benzyl]-N'-arylureas with weak toxicological effects on adrenal glands

A series of N-alkyl-N-[(fluorophenoxy)benzyl]-N'-arylureas were prepared and evaluated for their ability to inhibit intestinal acyl-CoA:cholesterol O- acyltransferase and to inhibit accumulation of cholesteryl esters in macrophages in vitro. In vivo hypocholesterolemic activity was assessed in cholesterol-fed rats by oral administration as a dietary admixture and/or by gavage in a PEG400 vehicle. Modification of the alkyl substituent on the N'- aryl moiety and on the urea nitrogen significantly influenced macrophage assay in vitro. Toxicological study revealed a distinct relationship between macrophage assay and the toxicity observed in adrenal glands of rabbits treated with representatives of this series of compounds. Investigations utilizing the macrophage assay as an indicator for adrenal toxicity led to the identification of compounds 1g (FR190809) and 1k (FR186485, or FR195249 as its hydrochloride salt) as potent, nonadrenotoxic, orally efficacious ACAT inhibitors irrespective of the administration method.

Platelet activating factor antagonists

Platelet activating factor antagonists of formula (I): STR1 wherein R is phenyl or phenyl substituted by one or more substituents selected from nitro, halo, C1 -C4 alkyl, C1 -C4 alkoxy, aryl (C1 -C4) alkoxy, fluoro (C1 -C4) alkoxy, C1 -C4 alkylthio, C1 -C4 alkylsulphonyl, hydroxy, trifluoromethyl and cyano, or is phenyl fused to a dioxole ring; R1 and R2 are each independently H or C1 -C6 alkyl, or R1 and R2 together complete a pyrrolidinyl, piperidino, morpholino, piperazinyl, N-(C1 -C4 alkyl) piperazinyl or N-(C2 -C4 alkanoyl)-piperazinyl group; or R2 is H or C1 -C4 alkyl and R1 is CN, C3 -C7 cycloalkyl, aryl, heteroaryl or a C1 -C4 alkyl group substituted by one or more substituents selected from C3 -C7 cycloalkyl, C1 -C4 alkoxycarbonyl, aryl or heteroaryl; Z is selected from C1 -C6 alkoxy, aryl (C1 -C4) alkoxy, hydroxy, and --NR4 R5 wherein each of R4 and R5 is independently H or C1 -C6 alkyl, or R4 and R5 together complete a pyrrolidinyl, piperidino, morpholino, piperazinyl or N-(C1 -C4 alkyl) piperazinyl group; Y is 1,4 phenylene or pyridine-2,5-diyl, and X is a 5 or 6 membered aromatic heterocyclic group containing one or more nitrogen atoms in its ring; which ring may be fused to a benzene ring or to a further 5- or 6-membered aromatic heterocyclic ring containing one or more nitrogen atoms, at least one of said heterocyclic rings optionally also containing an oxygen or sulphur atom, and being optionally substituted with one or more substituents selected from C1 -C4 alkyl, C1 -C4 alkoxy, halo, CF3 and CN; and their pharmaceutically acceptable salts.

1,4-dihydropyridine derivatives

The invention provides compounds of the formula STR1 and pharmaceutically acceptable salts thereof, wherein R is phenyl substituted by halo; R1 is C1 -C4 alkyl; is hydrogen, C5 -C7 cycloalkyl, benzyl

Pyrido[3,4-e]-1,2,4-triazines and related heterocycles as potential antifungal agents

The preparation and biological activities of a series of pyrido[3,4-e]-1,2,4-triazines, 1,2,4-triazino[5,6-c]quinolines, and related fused triazines are described. Methyl, amino, and acylamino substituents were placed in the pyridyl ring of the former system. Other structural modifications included various alkyl, cycloalkyl, substituted phenyl, and heterocyclic groups in the 3-position of these ring systems. In agar dilution assays, actives in this series inhibited strains of Candida, Aspergillus, Mucor, and Trychophyton species at MIC's of ≤ 16 μg/mL.